Johnson & Johnson (NYSE:JNJ) unit Janssen Pharmaceutical Companies reports positive six-month data from a Phase 1/2 clinical trial evaluating gene therapy AAV-RPGR in patients with X-linked retinitis pigmentosa, a group of inherited retinal disorders characterized by progressive vision loss.
Preliminary results showed that low and intermediate doses were generally well-tolerated and indicated significant improvements in vision.
A pre-recorded webcast on the data is available via http://www.investor.jnj.com and selecting “Webcasts/Presentations.”
Development is ongoing.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.